Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - KIWA BIO-TECH PRODUCTS GROUP CORPs102155_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - KIWA BIO-TECH PRODUCTS GROUP CORPs102155_ex31-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended September 30, 2015

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from ______ to ______

 

Commission File Number: 000-33167

 

KIWA BIO-TECH PRODUCTS GROUP CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   77-0632186
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
310 N. Indian Hill Blvd., #702
Claremont, California
  91711
(Address of principal executive offices)   (Zip Code)
     

(626) 715-5855

(Registrant’s telephone number, including area code)

     
  (Former address)  

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x           No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x           No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨   Accelerated filer ¨
Non-accelerated filer ¨   Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨       No x

 

There were 400,000,000 shares of the issuer’s common stock outstanding as of November 13, 2015.

 

1
 

 

Table of contents

 

PART I. FINANCIAL INFORMATION 1
     
ITEM 1. FINANCIAL STATEMENTS 1
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 10
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 14
ITEM 4. CONTROLS AND PROCEDURES 14
     
PART II. OTHER INFORMATION 16
     
ITEM 1. LEGAL PROCEEDINGS 16
ITEM 1A. RISK FACTORS 16
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 16
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 16
ITEM 4. MINE SAFETY DISCLOSURES 16
ITEM 5. OTHER INFORMATION 16
ITEM 6. EXHIBITS 17
     
SIGNATURES 18

 

i
 

 

KIWA BIO-TECH PRODUCTS GROUP CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)

 

   September 30,   December 31, 
   2015   2014 
           
ASSETS          
Current assets          
Cash and cash equivalents  $3,080   $2,963 
Deposits and other receivables   13,791    14,280 
Total current assets   16,871    17,243 
Property, plant and equipment - net   3,926    7,372 
Total assets  $20,797   $24,615 
LIABILITIES AND STOCKHOLDERS’ DEFICIENCY          
Current liabilities          
Accounts payable  $305,998   $316,842 
Advances from customers   14,064    14,562 
Construction costs payable   278,965    288,851 
Due to related parties - trade   1,107,829    1,025,057 
Due to related parties - non-trade   4,154,047    4,190,315 
Convertible notes payable   150,250    150,250 
Salary payable   1,628,326    1,538,266 
Taxes payable   471,976    440,885 
Penalty payable   386,205    332,600 
Interest payable   155,081    138,224 
Other payable   502,806    525,488 
Total current liabilities   9,155,547    8,961,340 
           
Unsecured loans payable   1,807,096    1,871,136 
Total long-term liabilities   1,807,096    1,871,136 
Total liabilities   10,962,643    10,832,476 
           
Stockholders’ deficiency          
Common stock - $0.001 par value. Authorized 400,000,000 shares. Issued and outstanding 400,000,000 shares at September 30, 2015 and December 31, 2014   400,000    400,000 
Preferred stock - $0.001 par value. Authorized 20,000,000 shares, none issued        
Additional paid-in capital   8,093,337    8,093,337 
Accumulated deficit   (19,020,705)   (18,608,154)
Accumulated other comprehensive loss   (414,478)   (693,044)
Total stockholders’ deficiency   (10,941,846)   (10,807,861)
Total liabilities and stockholders’ deficiency  $20,797   $24,615 

  

The accompanying notes are an integral part of these consolidated financial statements.

 

1
 

 

KIWA BIO-TECH PRODUCTS GROUP CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)

                 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2015   2014   2015   2014 
Revenue  $   $   $   $ 
                     
Operating expenses                    
General and administrative   72,968    82,690    220,510    254,888 
Research and development   39,860    40,661    121,487    121,750 
Total operating expenses   112,828    123,351    341,997    376,638 
Operating loss   (112,828)   (123,351)   (341,997)   (376,638)
                     
Other income (expense)                    
Penalty expense   (18,208)   (16,855)   (53,605)   (49,406)
Interest expense   (5,689)   (5,708)   (16,949)   (17,614)
Total other income (expense)   (23,897)   (22,563)   (70,554)   (67,020)
Net loss before income tax   (136,725)   (145,914)   (412,551)   (443,658)
Income tax                
Net loss   (136,725)   (145,914)   (412,551)   (443,658)
                     
Other comprehensive income (loss)                    
Foreign currency translation adjustment   327,472    (82,962)   278,566    105,414 
Total comprehensive income (loss)  $190,747   $(228,876)  $(133,985)  $(338,244)
                     
Net loss per common share - basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.00)
Weighted average number of common shares outstanding - basic and diluted   400,000,000    400,000,000    400,000,000    400,000,000 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2
 

  

KIWA BIO-TECH PRODUCTS GROUP CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 

         
   Nine Months Ended September 30, 
   2015   2014 
Cash flows from operating activities:          
Net loss  $(412,551)  $(443,658)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   3,293    3,298 
Provision for penalty payable   53,605    49,407 
Accrued interest on convertible notes   16,857    16,857 
Changes in operating assets and liabilities:          
Salary payable   110,604    151,907 
Taxes payable   47,604    47,676 
Due to related parties - trade   121,487    121,672 
Other payable   (18,752)   (60,656)
Net cash used in operating activities   (77,853)   (113,497)
           
Cash flows from financing activities:          
Proceeds from related parties, net of payments to related parties   77,988    115,826 
Net cash provided by financing activities   77,988    115,826 
Effect of exchange rate change   (18)   (50)
           
Cash and cash equivalents:          
Net increase   117    2,279 
Balance at beginning of period   2,963    2,039 
Balance at end of period  $3,080   $4,318 
           
Supplemental Disclosures of Cash flow Information:          
Cash paid for interest  $   $ 
Cash paid for income taxes  $   $ 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3
 

 

KIWA BIO-TECH PRODUCTS GROUP CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)

 

1. Description of Business and Organization

 

References herein to “Kiwa” or the “Company” refer to Kiwa Bio-Tech Products Group Corporation and its wholly-owned subsidiaries unless the context specifically states or implies otherwise.

 

Business –The Company’s business plan is to develop, manufacture, distribute and market innovative, cost-effective and environmentally safe bio-technological products for agriculture markets located primarily in China. The Company has acquired technologies to produce and market bio-fertilizer.

 

2. Going Concern

 

The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not purport to represent the realizable or settlement values.

  

As of September 30, 2015, the Company had cash of $3,080 and working capital deficiency of $9,138,676. The Company had an accumulated deficit of $19,020,705, and incurred net losses of $412,551 during the nine months ended September 30, 2015. This trend is expected to continue. These factors, among others, create substantial doubt about the Company’s ability to continue as a going concern. The Company will rely on the proceeds from the sale of securities and loans from both related parties and unrelated parties to provide the resources necessary to fund the operation.

 

The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

3. Summaries of Significant Accounting Policies

 

Principle of consolidation - These consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries. All significant inter-company balances or transactions are eliminated on consolidation.

 

Basis of preparation - These interim consolidated financial statements are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included. The results reported in the consolidated financial statements for any interim periods are not necessarily indicative of the results that may be reported for the entire year or any other periods. The (a) consolidated balance sheet as of December 31, 2014, which was derived from audited financial statements, and (b) the unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

 

Use of Estimates - The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates include the bad debt provision, impairment of inventory and long-lived assets, depreciation and amortization, valuation allowance of deferred tax assets and fair value of warrants and options.

 

4
 

 

Foreign Currency Translation - The Company uses United States dollars (“US Dollar” or “US$” or “$”) for financial reporting purposes. However, the Company maintains the books and records in its functional currency, Chinese Renminbi (“RMB”), being the primary currency of the economic environment in which its operations are conducted. In general, the Company translates its assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statement of income is translated at average exchange rates during the reporting period. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the Company’s financial statements are recorded as accumulated other comprehensive income.

 

The exchange rates used to translate amounts in RMB into U.S. Dollars for the purposes of preparing the condensed consolidated financial statements were as follows:

 

    As of September 30, 2015   As of December 31, 2014
Balance sheet items, except for equity accounts   US$1 = RMB 6.3638   US$1 = RMB 6.1460

 

    Nine months ended September 30,
    2015   2014
Items in the statements of income and cash flows   US$1 = RMB 6.1735   US$1 = RMB 6.1641

 

Research and development costs - Research and development costs are charged to expense as incurred.

 

Impairment of Long-Lived Assets - We periodically evaluate our investment in long-lived assets, including property and equipment, for recoverability whenever events or changes in circumstances indicate the net carrying amount may not be recoverable. Our judgments regarding potential impairment are based on legal factors, market conditions and operational performance indicators, among others. In assessing the impairment of property and equipment, we make assumptions regarding the estimated future cash flows and other factors to determine the fair value of the respective assets. Based on our analysis, no further impairment on long-lived assets was charged during the nine months ended September 30, 2015.

 

Income Taxes - The Company accounts for income taxes under the provisions of FASB ASC Topic 740, “Income Tax,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are recognized for the future tax consequence attributable to the difference between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company establishes a valuation when it is more likely than not that the assets will not be recovered.

 

Net Loss Per Common Share - Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share includes the effect of dilutive securities (stock options, warrants, convertible debt, stock subscription and other stock commitments issuable). These potentially dilutive securities were not included in the calculation of loss per share for the periods presented because the Company incurred a loss during such periods and thus the effect would have been anti-dilutive. Accordingly, basic and diluted loss per common share is the same for all periods presented. As of September 30, 2015, potentially dilutive securities aggregated 242,017,664 shares of common stock.

 

5
 

 

Fair value measurements - ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The carrying values of cash and cash equivalents, trade receivables and payables, and short-term debts approximate their fair values due to their short maturities.

 

There were no assets and liabilities measured at fair value on a nonrecurring basis as of September 30, 2015 and December 31, 2014.

 

4. Related Party Transactions

  

Amounts due to related parties consisted of the following as of September 30, 2015 and December 31, 2014:

 

Item  Nature   Notes         
           Sept. 30, 2015   Dec. 31, 2014 
Mr. Wei Li (“Mr. Li”)   Non-trade    (1)  $3,437,650   $3,553,939 
Kangtai Xinnong Agriculture  Tech (Beijing) Co., Ltd. (“Kangtai”)   Non-trade    (2)   (12,676)   (13,624)
Ms. Yvonne Wang (“Ms. Wang”)   Non-trade    (3)   729,073    650,000 
Subtotal             4,154,047    4,190,315 
                     
Kiwa-CAU R&D Center   Trade    (4)   1,107,829    1,025,057 
Subtotal             1,107,829    1,025,057 
Total            $5,261,876   $5,215,372 

 

The amounts due to related parties are non-interest bearing and due on demand.

 

(1)     Mr. Li

  

Mr. Li is the Chairman of the Board and was the Chief Executive Officer of the Company until July 1, 2015.

 

Advances and Loans

  

The remaining balance due to Mr. Li was $3,437,650 and $3,553,939 as of September 30, 2015 and December 31, 2014, respectively. Mr. Li has agreed that the Company may repay the balance when its cash flow circumstance allows.

 

Guarantees for the Company

 

Mr. Li has pledged without any compensation from the Company, all of his common stock of the Company as collateral security for the Company’s obligations under the 6% Notes (See Note 5 below).

 

(2)     Kangtai

 

Kangtai, formerly named Kangtai International Logistics (Beijing) Co., Ltd., is a private company, 28% owned by Mr. Li. Mr. Li is the Chairman of Kangtai.

 

6
 

 

On December 31, 2014, the amount due from Kangtai was $13,624. The balance due from Kangtai on September 30, 2015 was $12,676.

 

(3)     Ms. Wang

 

Ms. Wang is the Secretary of the Company.

 

On December 31, 2014, the amount due to Ms. Wang was $650,000. During the nine months ended September 30, 2015, Ms. Wang paid various expenses on behalf of the Company. As of September 30, 2015, the amount due to Ms. Wang was $729,073. Ms. Wang has agreed that the Company may repay the balance when its cash flow circumstance allows.

 

(4)     Kiwa-CAU R&D Center

 

Pursuant to the agreement with China Agricultural University (“CAU”), the Company agreed to invest RMB 1 million (approximately $157,000) each year to fund research at Kiwa-CAU R&D Center. Prof. Qi Wang, one of the Company’s directors, is also the director of Kiwa-CAU R&D Center (see Note 7).

 

On December 31, 2014, the amount due to Kiwa-CAU R&D Center was $1,025,057. As of September 30, 2015, the outstanding balance due to Kiwa-CAU R&D Center was $1,107,829.

 

5. Convertible Notes Payable

 

Convertible notes payable consists convertible notes issued on June 29, 2006, bear interest at 6% and matured on June 29, 2009. As of September 30, 2015 and December 31, 2014, balance of convertible notes payable was $150,250. As of September 30, 2015, interest payable on the convertible was $155,081. The Company also recorded liquidation damages of $386,205 as of September 30, 2015. No payment was made for interest and liquidation damages during the nine months ended September 30, 2015 and 2014, respectively.

 

6. Stock-based Compensation

 

On December 12, 2006, the Company granted options for 2,000,000 shares of its common stock under its 2004 Stock Incentive Plan. Summary of options issued and outstanding at September 30, 2015 and the movements during the nine months then ended are as follows:

 

    Number of
underlying
shares
  Weighted-
Average
Exercise
Price
Per Share
  Aggregate
Intrinsic
Value (1)
  Weighted-
Average
Contractual Life
Remaining in
Years
                 
Outstanding at December 31, 2014    1,232,600   $0.175   $    4 
Exercised                   
Expired                   
Forfeited                   
Outstanding at September 30, 2015    1,232,600   $0.175   $    3.25 
Exercisable at September 30, 2015    1,232,600   $0.175   $    3.25 

  

(1) The market value of the Company’s common stock at September 30, 2015 was $0.0012 per share. The outstanding options had no intrinsic value at September 30, 2015.

 

7. Commitments and Contingencies
   

The Company has the following material contractual obligations:

  

Operation of Kiwa-CAU R&D Center

 

Pursuant to the agreement on joint incorporation of the research and development center between CAU and Kiwa Shandong dated November 14, 2006, Kiwa Shandong agrees to invest RMB1 million (approximately $157,000) each year to fund research at the R&D Center. The term of this Agreement is ten years starting from July 1, 2006. Qi Wang, one of our directors commencing in July 2007 has acted as Director of Kiwa-CAU R&D Center since July 2006.

 

7
 

 

Investment in manufacturing and research facilities in Zoucheng, Shandong Province in China

 

According to the Project Agreement with Zoucheng Municipal Government in 2002, the Company has committed to investing approximately $18 million to $24 million for developing the manufacturing and research facilities in Zoucheng, Shandong Province. The Company had invested approximately $2 million for the project during the period from 2004 to 2010 and no additional investments were made since then.

 

8. Income Tax

  

No provision for taxes is made as the Company and its subsidiaries do not have any taxable income in the U.S., the British Virgin Islands or the PRC.

  

A reconciliation of U.S. tax rate of 34% to the Company’s effective tax rate is as follows:

  

   Nine Months ended Sept 30, 
   2015   2014 
         
Pre-tax income (loss)  $(412,551)  $(443,658)
           
U.S. federal corporate income tax rate   34%   34%
Income tax computed at U.S. federal corporate income tax rate   (140,267)   (150,844)
Reconciling items:          
Rate differential for PRC earnings   17,465    22,062 
Change of valuation allowance   92,202   98,182
Non-deductible expenses   30,600    30,600 
Effective tax expense  $   $ 

 

The Company had deferred tax assets as follows:

 

   September 30,   December 31 
   2015   2014 
           
Net operating losses carried forward  $3,038,886   $3,167,589 
Less: Valuation allowance   (3,038,886)   (3,167,589)
           
Net deferred tax assets  $   $ 

 

The net operating losses carried forward were approximately $7.4 million at September 30, 2015, which will expire between 2015 and 2025. Full valuation allowance has been made because it is considered more likely than not that the deferred tax assets will not be realized through sufficient future earnings of the entity to which the operating losses relate.

 

8
 

 

9. Subsequent Event

 

On November 5, 2015, the Company entered into a strategic cooperation agreement (the "Agreement") with the Institute of Agricultural Resources and Regional Planning, Chinese Academy of Agricultural Sciences (IARRP; CAAS) located in Beijing, the Peoples Republic of China (the "Institute of Agricultural Resources and Regional Planning"), and the Institute of Agricultural Economics and Development (IAED; CAAS) located in Beijing, the Peoples Republic of China (the "Institute of Agricultural Economics and Development"), for the purpose of establishing a strategic cooperative partnership with the Institute of Agricultural Resources and Regional Planning and the Institute of Agricultural Economics and Development to build an Internet-based, safe agricultural produce international cooperation platform. The platform will help the Company to further develop the National Standards for not only bio-tech products, but also safe agricultural produce and a safe system for agriculture industry chain in China. In accordance with the terms of the Agreement, the Company will provide to an innovation team of the Institute of Resources and Planning 1,000,000 Yuan (approximately US $160,000) per year for platform R&D expenses. The term of the Agreement is for three years beginning November 20, 2015.

  

9
 

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

This Quarterly Report on Form 10-Q for the three months ended September 30, 2015 contains “forward-looking statements” within the meaning of the federal securities laws, including statements that include the words “believes,” “expects,” “anticipates,” or similar expressions. These forward-looking statements include, among others, statements concerning our expectations regarding our working capital requirements, financing requirements, business, growth prospects, competition and results of operations, and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts. The forward-looking statements in this Quarterly Report on Form 10-Q for the three months ended September 30, 2015 involve known and unknown risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by the forward-looking statements contained herein.

 

Overview

 

The Company took its present corporate form in March 2004 when shareholders of Kiwa Bio-Tech Products Group Ltd. (“Kiwa BVI”), a company originally organized under the laws of the British Virgin Islands on June 5, 2002 and Tintic Gold Mining Company (“Tintic”), a corporation originally incorporated in the state of Utah on June 14, 1933 to perform mining operations in Utah, entered into a share exchange transaction. The share exchange transaction left the shareholders of Kiwa BVI owning a majority of Tintic and Kiwa BVI a wholly-owned subsidiary of Tintic. For accounting purposes this transaction was treated as an acquisition of Tintic by Kiwa BVI in the form of a reverse triangular merger and a recapitalization of Kiwa BVI and its wholly owned subsidiary, Kiwa Bio-Tech Products (Shandong) Co., Ltd. (“Kiwa Shandong”). On July 21, 2004, we completed our reincorporation in the State of Delaware.

 

We have established a subsidiary in China, Kiwa Shandong in 2002, a wholly-owned subsidiary, engaging in the bio-fertilizer business. Formerly, our subsidiary Tianjin Kiwa Feed Co., Ltd. (“Kiwa Tianjin”), was engaged in the bio-enhanced feed business. At the end of 2009, Kiwa Tianjin could no longer use its assets including machinery and inventory in the normal course of operations. The Company has classified the bio-enhanced feed business as discontinued operations. Effective on July 11, 2012, the Company formally dissolved Kiwa Tianjin.

 

We generated no revenues in the nine months ended September 30, 2015 and 2014. We incurred a net loss of $412,551 and $443,658 for the nine months ended September 30, 2015 and 2014, respectively.

 

As of September 30, 2015, the Company had cash of $3,080. Due to our limited revenues from sales and continuing losses, we have relied on the proceeds from the sale of our equity securities and loans from both unrelated and related parties to provide the resources necessary to fund the development of our business plan and operations. During the nine months ended September 30, 2015, net amount advanced by related parties, net of repayment to related parties was $77,988 in total. These funds are insufficient to execute our business plan as currently contemplated. Management is currently looking for alternative sources of capital to fund our operations.

  

Going Concern

 

Our consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not purport to represent the realizable or settlement values.

 

As of September 30, 2015, we had an accumulated deficit of $19,020,705 of which $412,551 was incurred during the nine months ended September 30, 2015. We currently do not have sufficient revenues to support our business activities and we expect operating losses to continue. We will require additional capital to fund our operations.

 

As of September 30, 2015, our current liabilities were $9,155,547, which exceeded current assets by $9,138,676, representing a current ratio of 0.0018; comparably, as of December 31, 2014, we had total current assets of $17,243; at the same time, we had current liabilities of $8,961,340, denoting a current ratio of 0.0019. As of September 30, 2015, we also had long-term liabilities of $1,807,096. The 6% Notes became due on June 29, 2009. If we can achieve the necessary financing to increase our working capital, we believe the Company will be well-positioned to generate sales of our products and to generate more revenues in the future. There can be no assurances that we will be successful in obtaining this financing or in increasing our sales revenue if we do obtain the financing.

 

10
 

 

Our independent auditors have added an explanatory paragraph to their audit opinion issued in connection with our financial statements for the latest nine years, which states that the financial statements raise substantial doubt as to our ability to continue as a going concern. Our ability to make operations profitable or obtain additional funding will determine our ability to continue as a going concern.

 

Trends and Uncertainties in Regulation and Government Policy in China

 

Foreign Investment Policy Change in China

 

On March 16, 2007, China’s parliament, the National People’s Congress, adopted the Enterprise Income Tax Law, which took effective on January 1, 2008. The new income tax law sets a unified income tax rate for domestic and foreign companies at 25% and abolishes the favorable policy for foreign invested enterprises. As a result, subsidiaries established in China in the future will not enjoy the original favorable policy unless they are certified as qualified high and new technology enterprises.

 

According to the enterprise income tax law previously in effect, our PRC subsidiary, Kiwa Shandong, was exempt from corporate income taxes for its first two profitable years and was entitled to a 50% tax reduction for the succeeding three years. Now that the new income tax law is in effect, fiscal year 2008 is regarded as the first profitable year even if Kiwa Shandong was not profitable that year; thereby narrowing the time period when the favorable tax treatment may be available to us.

 

Critical Accounting Policies and Estimates

 

We prepared our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Management periodically evaluates the estimates and judgments made. Management bases its estimates and judgments on historical experience and on various factors that are believed to be reasonable under current circumstances. Actual results may differ from these estimates as a result of different assumptions or conditions.

 

The following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements. In addition, you should refer to our accompanying financial statements and the related notes thereto, for further discussion of our accounting policies.

 

Impairment of Long-Lived Assets

 

Our long-lived assets consist of property, equipment and intangible assets. As of September 30, 2015, the net value of property and equipment was $3,926, which represented approximately 18.9% of our total assets.

 

We periodically evaluate our investment in long-lived assets, including property and equipment, for recoverability whenever events or changes in circumstances indicate the net carrying amount may not be recoverable. Our judgments regarding potential impairment are based on legal factors, market conditions and operational performance indicators, among others. In assessing the impairment of property and equipment, we make assumptions regarding the estimated future cash flows and other factors to determine the fair value of the respective assets. If these estimates or the related assumptions change in the future, we may be required to record impairment charges for these assets.

 

Based on our analysis, no further impairment on long-lived assets was charged during the nine months ended September 30, 2015.

 

11
 

 

Income Taxes

 

The Company accounts for income taxes under the provisions of FASB ASC Topic 740, “Income Tax,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are recognized for the future tax consequence attributable to the difference between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company establishes a valuation when it is more likely than not that the assets will not be recovered.

 

Major Customers and Suppliers

 

Bio-fertilizer Products

 

As of September 30, 2015 and 2014, we had no customers. During the nine months ended September 30, 2015 and 2014, we had no suppliers.

 

Results of Operations

 

Results of Operations for Three Months Ended September 30, 2015 and 2014

 

Revenue

 

Net sales were nil for the three months ended September 30, 2015 and 2014, respectively. The Company did not generate any sales revenue during the third quarter of 2015 and 2014 mainly due to severe market conditions.

 

General and Administration

 

General and administration expenses for the three months ended September 30, 2015 and 2014 were $72,968 and $82,690, respectively, representing a $9,722 or 12% decrease. General and administrative expenses include salaries, travel and entertainment, rent, office expense, telephone expense and insurance costs. The decrease in general and administrative expenses was mainly due to decreased amount of salary and rent expenses incurred by the Company during the current period as compared with the same period of last year.

 

Research and Development

 

Research and development expense for the three months ended September 30, 2015 reflected a slight decrease of $801 or 2% from $40,661 in the three months ended September 30, 2014 to $39,860 for the same period of 2015 because of exchange rate effect.

 

Penalty Expense

 

The Company incurred liquidated damages resulting from the default of its 6% Notes (defined below). The penalty charge, which is calculated monthly at 2% of the outstanding amounts of convertible notes and unpaid interest on the notes, was $18,208 and $16,855 for the three months ended September 30, 2015 and 2014, respectively. The increase of penalty expense was mainly due to the increase of accrued and unpaid interest on the notes.

  

Interest Expenses

 

Net interest expense was $5,689 in the three months ended September 30, 2015 and $5,708 in the same period of 2014, representing a $19 or 0.3% decrease.

 

12
 

 

Net Loss

 

During the three months ended September 30, 2015, net loss was $136,725, comparing with $145,914 for the same period of 2014, representing a decrease of $9,189 or 6.3%. The decrease is mainly because of decrease in general and administrative expenses in the quarter especially salary and rent, partially offset by increase of penalty expense described above.

 

Comprehensive Loss

 

Comprehensive income for the three months ended September 30, 2015 was $190,747, as compared to comprehensive loss of $228,876 for the same period ended September 30, 2014. This increase resulted from increase in foreign currency translation adjustments of $410,434 in addition to the other reasons stated above.

 

Results of Operations for Nine Months Ended September 30, 2015 and 2014

 

Revenue

 

Net sales were nil for the nine months ended September 30, 2015 and 2014, respectively. The Company did not generate any sales revenue during the nine months ended September 30, 2015 and 2014 mainly due to severe market conditions.

 

General and Administration

 

General and administration expenses for nine months ended September 30, 2015 and 2014 were $220,510 and $254,888, respectively, representing a $34,378 or 13.5% decrease. General and administrative expenses include salaries, travel and entertainment, rent, office expense, telephone expense and insurance costs. The decrease in general and administrative expenses was mainly due to decreased amount of salary and rent expenses incurred by the Company during current period as compared with same period of last year.

 

Research and Development

 

Research and development expense for the nine months ended September 30, 2015 reflected a slight decrease of $263 or less than 1% from $121,750 in the nine months ended September 30, 2014 to $121,487 for the same period of 2015 because of exchange rate effect.

 

Penalty Expense

 

The Company incurred liquidated damages resulting from the default of its 6% Notes. The penalty charge, which is calculated monthly at 2% of the outstanding amounts of convertible notes and unpaid interest on the notes, was $53,605 and $49,406 for the nine months ended September 30, 2015 and 2014, respectively. The increase of penalty expense was mainly due to the increase of accrued and unpaid interest on the 6% Notes.

 

Interest Expenses

 

Net interest expense was $17,614 in the nine months ended September 30, 2014 and $16,949 in the same period of 2015, representing a $665 or 3.8% decrease.

 

Net Loss

 

During the nine months ended September 30, 2015, net loss was $412,551, comparing with $443,658 for the same period of 2014, representing a decrease of $31,107 or 7%. The decrease is mainly because of decrease in general and administrative expenses especially salary and rent, partially offset by increase of penalty expense described above.

 

Comprehensive Loss

 

Comprehensive loss decreased by $204,259 or 60% from $338,244 for the nine months ended September 30, 2014, as compared to $133,985 for the comparable period of 2015. This decrease in comprehensive loss resulted from increase in foreign currency translation adjustments of $173,152, in addition to the decrease in net loss described above.

 

13
 

 

Liquidity and Capital Resources

 

Since inception of our ag-biotech business in 2002, we have relied on proceeds from sale of our equity securities and loans from both unrelated and related parties to provide the resources necessary to fund our operations and the execution of our business plan. During the nine months ended September 30, 2015, the amount related parties advanced to the Company, net of repayment by the Company to related parties was $77,988. As of September 30, 2015, our current liabilities exceeded current assets by $9,138,676, reflecting a current ratio of 0.0018. Comparably, as of December 31, 2014, our current liabilities exceeded current assets by $8,944,097, denoting a current ratio of 0.0019.

 

As of September 30, 2015 and December 31, 2014, we had cash of $3,080 and $2,963, respectively. Changes in cash balances are outlined as follows:

 

During the nine months ended September 30, 2015, our operations utilized cash of $77,853 as compared with $113,497 in the same period of 2014. Cash was mainly used for working capital for public company operation.

 

During the nine months ended September 30, 2015 and 2014, we invested nil for investing activities.

 

During the nine months ended September 30, 2015, our financing activities incurred net cash inflow of $77,988, all of which were generated from advances or loans from related parties, net of repayment to related parties. During the same period ended September 30, 2014, we generated $115,826 from financing activities.

 

Currently, we have insufficient cash resources to accomplish our objectives and also do not anticipate generating sufficient positive operating cash inflow in the rest of 2015 to fund our planned operations. We are actively looking for new sources of capital. To the extent that we are unable to successfully raise the capital necessary to fund our future cash requirements on a timely basis and under acceptable terms and conditions, we will not have sufficient cash resources to maintain operations, and may have to curtail operations and consider a formal or informal restructuring or reorganization.

 

Commitments and Contingencies

 

See Note 7 to the Consolidated Financial Statements under Item 1 in Part I.

 

Subsequent Event

 

On November 5, 2015, we entered into a strategic cooperation agreement (the “Agreement”) with the Institute of Agricultural Resources and Regional Planning, Chinese Academy of Agricultural Sciences (IARRP; CAAS) located in Beijing, the Peoples Republic of China (the “Institute of Agricultural Resources and Regional Planning”), and the Institute of Agricultural Economics and Development (IAED; CAAS) located in Beijing, the Peoples Republic of China (the “Institute of Agricultural Economics and Development”), for the purpose of establishing a strategic cooperative partnership with the Institute of Agricultural Resources and Regional Planning and the Institute of Agricultural Economics and Development to build an Internet-based, safe agricultural produce international cooperation platform. The platform will help the Company to further develop the National Standards for not only bio-tech products, but also safe agricultural produce and a safe system for agriculture industry chain in China. In accordance with the terms of the Agreement, we will provide to an innovation team of the Institute of Resources and Planning 1,000,000 Yuan (approximately US $160,000) per year for platform R&D expenses. The term of the Agreement is for three years beginning November 20, 2015.

 

Off-Balance Sheet Arrangements

 

At September 30, 2015, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls.

 

Our management, under the supervision and with the participation of our Chief Executive and Interim Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in SEC Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this Quarterly Report. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934 (“Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the SEC’s forms, and that such information is accumulated and communicated to our management including our Chief Executive and Interim Chief Financial Officer, to allow timely decisions regarding required disclosures. Based on his evaluation, our Chief Executive and Interim Chief Financial Officer concluded that, as of September 30, 2015, our disclosure controls and procedures were ineffective.

 

14
 

 

Our management has conducted, with the participation of our Chief Executive and Interim Chief Financial Officer, an assessment, including testing of the effectiveness, of our disclosure controls and procedures as of September 30, 2015. Based on such evaluation, management identified deficiencies that were determined to be a material weakness.

 

A material weakness is a deficiency, or a combination of deficiencies, in disclosure controls and procedures, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Because of the material weaknesses described below, management concluded that our disclosure controls and procedures were ineffective as of September 30, 2015.

 

The specific material weakness identified by the Company’s management as of September 30, 2015are described as follows:

 

  l The Company is lacking qualified resources to perform the internal audit functions properly. In addition, the scope and effectiveness of the Company’s internal audit function are yet to be developed.
  l We currently do not have an audit committee.

 

Remediation Initiative

 

  l We are committed to establishing the disclosure controls and procedures but due to limited qualified resources in the region, we were not able to hire sufficient internal audit resources by September 30, 2015. However, internally we established a central management center to recruit more senior qualified people in order to improve our internal control procedures. Externally, we are looking forward to engaging an accounting firm to assist the Company in improving the Company’s internal control system based on the COSO Framework. We also will increase our efforts to hire the qualified resources.

  l We intend to establish an audit committee of the board of directors as soon as practicable. We envision that the audit committee will be primarily responsible for reviewing the services performed by our independent auditors, evaluating our accounting policies and our system of internal controls.

 

Conclusion

 

The Company did not have sufficient and skilled accounting personnel with an appropriate level of technical accounting knowledge and experience in the application of generally accepted accounting principles accepted in the United States of America commensurate with the Company’s disclosure controls and procedures requirements, which resulted in a number of deficiencies in disclosure controls and procedures that were identified as being significant. The Company’s management believes that the number and nature of these significant deficiencies, when aggregated, was determined to be a material weakness.

  

Despite of the material weaknesses and deficiencies reported above, the Company’s management believes that its condensed consolidated financial statements included in this report fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods presented and that this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Changes in internal control over financial reporting.

 

There were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

15
 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.

 

ITEM 1A. RISK FACTORS

 

Note: in addition to the other information set forth in this report, you should carefully consider the factors discussed in “Item 1A. Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 which could materially affect our business, financial condition, or future results. During the three months ended September 30, 2015, there were no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities 

 

On June 29, 2006, the Company entered into a securities purchase agreement with six institutional investors for the issuance and sale of (1) 6% secured convertible notes, due three years from the date of issuance, in the aggregate principal amount of $2,450,000, convertible into shares of the Company’s common stock (the “6% Notes”), and (2) warrants to purchase 12,250,000 shares of the Company’s common stock. The maturity date for 6% Notes was June 29, 2009.

 

On June 29, 2009, the 6% Notes were due. The Company had informed the Purchasers of its inability to repay the outstanding balance on the due date. Therefore, the 6% Notes were in default.

 

On January 31, 2008, the Company entered into three Callable Secured Convertible Notes Agreements (“2% Notes”) with four of the Company’s 6% Notes purchasers converting their unpaid interest of $112,917 in total, into principal with an interest rate of 2% per annum, which fell due on January 31, 2011. Other terms of the 2% Notes are similar to the 6% Notes.

 

On August 12, 2013, the Company entered into a Settlement Agreement and Release (the “Release”) with the Purchasers of the Company’s 6% Notes and 2% Notes. Pursuant to the terms of the Release, the Company paid the Purchasers $75,000 for a full release, including the forgiveness of past defaults of unpaid principal amounts, interest and penalties. As of September 30, 2015, principal amount of 6% Notes outstanding was $150,250; interest amount outstanding was $155,081; amount of standard liquidation damages was $386,205.

 

As of December 31, 2013, the 2% Notes have been fully settled.

 

Item 4. Mine safety disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

16
 

 

Item 6. Exhibits

 

Exhibit No.   Description   Incorporated by
Reference in
Document
  Exhibit No. in
Incorporated
Document
31.1/31/2   Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a) and Rule15d-14(a) of the Securities Exchange Act of 1934, as amended   Filed herewith.    
32.1/32.2*   Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   Filed herewith.    
101.INS   XBRL Instance Document   Filed herewith.    
101.SCH   XBRL Taxonomy Extension Schema Document   Filed herewith.    
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document   Filed herewith.    
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document   Filed herewith.    
101.LAB   XBRL Taxonomy Extension Label Linkbase Document   Filed herewith.    
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document   Filed herewith.    

 

*This certification is being furnished and shall not be deemed "filed" with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

 

17
 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

     
  KIWA BIO-TECH PRODUCTS GROUP CORPORATION
     
November 13, 2015 By:  /s/ Jimmy Ji Zhou
  Jimmy Ji Zhou, Chief Executive Officer and Interim Chief Financial Officer

  

18